State of the art: radiolabeled microspheres treatment for liver malignancies
- PMID: 20163269
- DOI: 10.1517/14656560903520916
State of the art: radiolabeled microspheres treatment for liver malignancies
Abstract
Importance of the field: Metastatic tumours of the liver are responsible for significant morbidity and mortality, and only a small percentage is resectable with curative intent. Hepatic artery radioembolization (RE) with yttrium-90 ((90)Y)-loaded microspheres is an alternative treatment for patients with unresectable primary or secondary liver tumours, especially in cases of metastatic colorectal cancer (mCRC) and hepatocellular carcinoma (HCC).
Areas covered in this review: Data from recent relevant clinical trials with (90)Y-RE are discussed, focusing on response rate assessments and treatment outcome.
What the reader will gain: Current data show that (90)Y-RE combined with radiosensitizing chemotherapy is a safe and efficient modality that extends the time to progression in liver mCRC and unresectable HCC, although no survival benefits have been demonstrated. The treatment response after (90)Y-RE seems to be better assessed using metabolic response assessments with serial fluorodeoxyglucose positron emission tomography (FDG-PET) in cases of FDG-avid tumours than with morphological criteria measured on computed tomography or magnetic resonance imaging (RECIST or WHO trials). Predictive models using multimodality imaging approaches (PET-SPECT-CT image fusion algorithms) have been proposed to better select patients for (90)Y-RE. The optimal routine role of radioembolization remains to be defined; the complexity and wide availability of available therapeutic alternatives confuses the role of a locoregional treatment in a generalized disease.
Take home message: (90)Y-RE is a safe and efficient treatment modality in salvage therapy of colorectal cancer metastatic to the liver and in unresectable HCC. However, it has still to find its place as a first- or second-line treatment of mCRC in combination with or as an alternative to available biological agents. The role of (90)Y-RE in other solid tumour types metastatic to the liver is much more uncertain and investigations in clinical situations in which disease is strictly limited to the liver are required. Pretherapeutic work-up, initially developed to explore hepatic vasculature and to assess lung shunting, might be able to predict treatment outcome, allowing a better patient selection.
Similar articles
-
Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.J Vasc Interv Radiol. 2008 Aug;19(8):1187-95. doi: 10.1016/j.jvir.2008.05.013. Epub 2008 Jun 27. J Vasc Interv Radiol. 2008. PMID: 18656012
-
Treatment of hepatocellular carcinoma by radioembolization using 90Y microspheres.Dig Dis. 2009;27(2):164-9. doi: 10.1159/000218349. Epub 2009 Jun 22. Dig Dis. 2009. PMID: 19546555 Review.
-
Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis.J Vasc Interv Radiol. 2010 Aug;21(8):1205-12. doi: 10.1016/j.jvir.2010.04.012. Epub 2010 Jul 3. J Vasc Interv Radiol. 2010. PMID: 20598574
-
90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging.J Vasc Interv Radiol. 2005 Dec;16(12):1641-51. doi: 10.1097/01.RVI.0000179815.44868.66. J Vasc Interv Radiol. 2005. PMID: 16371530 Clinical Trial.
-
Microsphere radioembolization of liver malignancies: current developments.Q J Nucl Med Mol Imaging. 2009 Jun;53(3):325-35. Q J Nucl Med Mol Imaging. 2009. PMID: 19521312 Review.
Cited by
-
Cryotherapy for liver metastases.Cochrane Database Syst Rev. 2019 Jul 10;7(7):CD009058. doi: 10.1002/14651858.CD009058.pub3. Cochrane Database Syst Rev. 2019. PMID: 31291464 Free PMC article.
-
Perfusion CT best predicts outcome after radioembolization of liver metastases: a comparison of radionuclide and CT imaging techniques.Eur Radiol. 2014 Jul;24(7):1455-65. doi: 10.1007/s00330-014-3180-3. Epub 2014 May 12. Eur Radiol. 2014. PMID: 24817083
-
Intra-arterial therapies for metastatic colorectal cancer.Semin Intervent Radiol. 2013 Mar;30(1):12-20. doi: 10.1055/s-0033-1333649. Semin Intervent Radiol. 2013. PMID: 24436513 Free PMC article. Review.
-
Pharmacotherapy of Zollinger-Ellison syndrome.Expert Opin Pharmacother. 2013 Feb;14(3):307-21. doi: 10.1517/14656566.2013.767332. Epub 2013 Jan 30. Expert Opin Pharmacother. 2013. PMID: 23363383 Free PMC article. Review.
-
Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances.J Gastroenterol. 2012 Sep;47(9):941-60. doi: 10.1007/s00535-012-0642-8. Epub 2012 Aug 11. J Gastroenterol. 2012. PMID: 22886480 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials